21 Jun 06
Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate
20 Jun 06
Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL
19 Jun 06
Cell Therapeutics has announced positive phase III data for Xyotax in non-small cell lung cancer, with the drug significantly increasing survival in pre-menopausal female patients with high estrogen levels. However, with such a limited patient population, Xyotax will struggle to compete with Sanofi-Aventis' Taxotere, Eli Lilly's Gemzar and genericized paclitaxel in cost-constrained markets.
19 Jun 06
In today's edition of DailyUpdates we report on CD40:CD40L. Traditionally a target for autoimmune/transplant therapeutics, we highlight a study supporting the development of blockers of CD40:CD40L as candidate treatments of Alzheimer's disease. We also highlight a new oncology candidate in development by Lorus
16 Jun 06
In today's edition of DailyUpdates we headline with news from CuraGen and TopoTarget on a new trial evaluating the combination of an HDAC inhibitor an cis-retinoid acid. In addition we highlight research from Wyeth suggesting a new approach to depression
14 Jun 06
Data presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta this month suggest that administering the epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab) fortnightly rather than weekly in metastatic colorectal cancer (mCRC) is a feasible option. Another study probing whether scaling up the dose, to the point where patients experience the significant rash linked to long survival, achieves a better response, shows high doses are well tolerated.
Olwen Glynn Owen - PharmiWeb Field Reporter
12 Jun 06
Vertex has launched a major phase II clinical trial to test a new hepatitis C drug candidate, with a second trial scheduled to begin in June. This is a significant advance in the development of much-needed treatments for hepatitis C. By drawing parallels with similar HIV treatments, Datamonitor's Morris Paterson outlines the pitfalls and prospects for this new drug.
Datamonitor Expert Views
12 Jun 06
Today's edition highlights news from Metabolex announcing the initiation of a Phase 2/3 trial of a novel insulin sensitizer, metaglidasen. In addition we discuss research published by Advanced Life Sciences who are making exciting breakthroughs moving towards the treatment of HIV Tuberculosis co-infection which has become a global catastrophe.
10 Jun 06
Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects for the future. With the FDA approval and commercialization of Velcade, scientists are now beginning to see the potential of this ever expanding science. New therapeutic targets are being explored and implica
09 Jun 06
Today we report on the FDA approval of Merck's HPV vaccine, the first such vaccine to be approved in the US; and a candidate treatment for various cardiovascular diseases
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.